A258540 Stock Overview
Engages in cell therapy and medical device businesses. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
SL Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩910.00 |
| 52 Week High | ₩2,260.00 |
| 52 Week Low | ₩503.00 |
| Beta | 0 |
| 11 Month Change | -1.52% |
| 3 Month Change | -16.21% |
| 1 Year Change | 10.98% |
| 33 Year Change | -83.45% |
| 5 Year Change | -87.59% |
| Change since IPO | -80.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| A258540 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | 16.1% | -9.0% | -2.8% |
| 1Y | 11.0% | 33.1% | -3.4% |
Return vs Industry: A258540 underperformed the KR Life Sciences industry which returned 33.1% over the past year.
Return vs Market: A258540 exceeded the KR Market which returned -3.4% over the past year.
Price Volatility
| A258540 volatility | |
|---|---|
| A258540 Average Weekly Movement | 14.9% |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A258540's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A258540's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | n/a | Jong Sung Choi | www.stemlab.co.kr |
SL Therapeutics, Inc. engages in cell therapy and medical device businesses. The company develops cell therapeutic solutions based on its cell reprogramming technology to treat various diseases with a focus on spinal cord injury, and age and genetically related diseases; and hair follicle cells, skin cells, and cells of the central nervous system. It also manufactures automated magnetic resonance imaging systems; and Supra Elite and Dexino bone mineral density measurement devices.
SL Therapeutics, Inc. Fundamentals Summary
| A258540 fundamental statistics | |
|---|---|
| Market cap | ₩4.74b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A258540 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A258540 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A258540 perform over the long term?
See historical performance and comparison